We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 13 augustus 2018

Leukemia - Table of Contents alert Volume 32 Issue 8

If you are unable to see the message below, click here to view.
Leukemia

Advertisement
See how droplets are guiding precision medicine

Do you have the tools you need to support clinicians at decisive moments? Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. See how a promising new technology lets you use this method to its fullest potential to give clinicians insights that can guide personalized cancer treatments and save lives.
 
TABLE OF CONTENTS

Volume 32, Issue 8

In this issue
Review Article
Article
Brief Communication
Also new
AOP
 
Advertisement
 
Now Enrolling - Clinical studies for oral pracinostat in Acute Myeloid Leukemia (AML) Patients Unfit for Induction Chemotherapy and in Myelodysplastic Syndromes (MDS) trials

Pracinostat is an investigational agent not approved for commercial use by the FDA or any other regulatory agency worldwide

PRAN-US-0024  

Review Article

Molecular remission as a therapeutic objective in acute promyelocytic leukemia

Laura Cicconi, Pierre Fenaux, Hagop Kantarjian, Martin Tallman, Miguel A. Sanz et al.

Leukemia 2018 32 :1671 - 1678; July 19, 2018; 10.1038/s41375-018-0219-5

 

Abstract | Full Text

Diagnostic algorithm for lower-risk myelodysplastic syndromes

Ghulam J. Mufti, Donal P. McLornan, Arjan A. van de Loosdrecht, Ulrich Germing & Robert P. Hasserjian

Leukemia 2018 32 :1679 - 1696; June 26, 2018; 10.1038/s41375-018-0173-2

 

Abstract | Full Text

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos, Ralph Wäsch et al.

Leukemia 2018 32 :1697 - 1712; April 25, 2018; 10.1038/s41375-018-0142-9

 

Abstract | Full Text

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer

Bettina Wingelhofer, Heidi A. Neubauer, Peter Valent, Xiaonan Han, Stefan N. Constantinescu et al.

Leukemia 2018 32 :1713 - 1726; March 27, 2018; 10.1038/s41375-018-0117-x

 

Abstract | Full Text

Article

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

Jennifer L. J. Heaney, John P. Campbell, Gulnaz Iqbal, David Cairns, Alex Richter et al.

Leukemia 2018 32 :1727 - 1738; June 20, 2018; 10.1038/s41375-018-0163-4

 

Abstract | Full Text

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche

Shokichi Tsukamoto, Marianne B. Løvendorf, Jihye Park, Karma Z. Salem, Michaela R. Reagan et al.

Leukemia 2018 32 :1739 - 1750; June 20, 2018; 10.1038/s41375-018-0161-6

 

Abstract | Full Text

Consequences of mutant TET2 on clonality and subclonal hierarchy

Cassandra M. Hirsch, Aziz Nazha, Kassy Kneen, Mohamed E. Abazeed, Manja Meggendorfer et al.

Leukemia 2018 32 :1751 - 1761; May 24, 2018; 10.1038/s41375-018-0150-9

 

Abstract | Full Text

Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita

Martin Kirschner, Angela Maurer, Marcin W. Wlodarski, Monica S. Ventura Ferreira, Anne-Sophie Bouillon et al.

Leukemia 2018 32 :1762 - 1767; April 02, 2018; 10.1038/s41375-018-0125-x

 

Abstract | Full Text

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin et al.

Leukemia 2018 32 :1768 - 1777; July 20, 2018; 10.1038/s41375-018-0210-1

 

Abstract | Full Text

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

Stephan Stilgenbauer, Veronique Leblond, Robin Foà, Sebastian Böttcher, Osman Ilhan et al.

Leukemia 2018 32 :1778 - 1786; April 27, 2018; 10.1038/s41375-018-0146-5

 

Abstract | Full Text

The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation

Joshua A. Fein, Avichai Shimoni, Myriam Labopin, Noga Shem-Tov, Ronit Yerushalmi et al.

Leukemia 2018 32 :1787 - 1794; June 27, 2018; 10.1038/s41375-018-0185-y

 

Abstract | Full Text

Brief Communication

Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia

Sarah D. Cramer, Julie A. Hixon, Caroline Andrews, Ross J. Porter, Gisele O. L. Rodrigues et al.

Leukemia 2018 32 :1795 - 1882; February 15, 2018; 10.1038/s41375-017-0001-0

 

Abstract | Full Text

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S Rule, W Jurczak, M Jerkeman, C Rusconi, M Trneny et al.

Leukemia 2018 32 :1799 - 1803; February 02, 2018; 10.1038/s41375-018-0023-2

 

Abstract | Full Text

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Sara Bringhen, Roberto Mina, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada et al.

Leukemia 2018 32 :1803 - 1807; January 30, 2018; 10.1038/s41375-018-0024-1

 

Abstract | Full Text

High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement

Roberta La Starza, Monica Messina, Valentina Gianfelici, Valentina Pierini, Caterina Matteucci et al.

Leukemia 2018 32 :1807 - 1810; February 02, 2018; 10.1038/s41375-018-0031-2

 

Abstract | Full Text

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance

Arjun Lakshman, Shilpa Paul, S. Vincent Rajkumar, Rhett P. Ketterling, Patricia T. Greipp et al.

Leukemia 2018 32 :1811 - 1815; January 30, 2018; 10.1038/s41375-018-0030-3

 

Abstract | Full Text

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used

Xavier Bossuyt, Michel Delforge, Martin Reynders, Doreen Dillaerts, Ben Sprangers et al.

Leukemia 2018 32 :1815 - 1818; April 20, 2018; 10.1038/s41375-018-0041-0

 

Abstract | Full Text

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells

Pedro Casado, Edmund H. Wilkes, Farideh Miraki-Moud, Marym Mohammad Hadi, Ana Rio-Machin et al.

Leukemia 2018 32 :1818 - 1822; April 07, 2018; 10.1038/s41375-018-0032-1

 

Abstract | Full Text

Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis

Julia Suárez-González, Carolina Martínez-Laperche, Nerea Martínez, Gabriela Rodríguez-Macías, Mi Kwon et al.

Leukemia 2018 32 :1822 - 1826; February 05, 2018; 10.1038/s41375-018-0042-z

 

Abstract | Full Text

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling

Francesca Pagano, Federico Comoglio, Jacob Grinfeld, Juan Li, Anna Godfrey et al.

Leukemia 2018 32 :1826 - 1830; February 27, 2018; 10.1038/s41375-018-0053-9

 

Abstract | Full Text

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses

Tsewang Tashi, Sabina Swierczek, Soo Jin Kim, Mohamed E. Salama, Jihyun Song et al.

Leukemia 2018 32 :1830 - 1833; February 28, 2018; 10.1038/s41375-018-0080-6

 

Abstract | Full Text

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo

Ying Guo, Hui Yang, Shi Chen, Peng Zhang, Rong Li et al.

Leukemia 2018 32 :1834 - 1837; April 02, 2018; 10.1038/s41375-018-0126-9

 

Abstract | Full Text

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

Guangwu Guo, Noopur S. Raje, Charles Seifer, Jake Kloeber, Randi Isenhart et al.

Leukemia 2018 32 :1838 - 1841; March 27, 2018; 10.1038/s41375-018-0115-z

 

Abstract | Full Text

JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation

Wenbin Xiao, Raajit Rampal, Yanming Zhang, Robert Cimera, Achim A. Jungbluth et al.

Leukemia 2018 32 :1842 - 1845; April 24, 2018; 10.1038/s41375-018-0145-6

 

Abstract | Full Text

An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS

Jun-ichiro Kida, Takayuki Tsujioka, Shin-ichiro Suemori, Shuichiro Okamoto, Kanae Sakakibara et al.

Leukemia 2018 32 :1846 - 1850; June 28, 2018; 10.1038/s41375-018-0189-7

 

Abstract | Full Text

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone

Mrinal M. Patnaik, Rangit Vallapureddy, Terra L. Lasho, Katherine P. Hoversten, Christy M. Finke et al.

Leukemia 2018 32 :1850 - 1856; April 02, 2018; 10.1038/s41375-018-0121-1

 

Abstract | Full Text

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Ashfaq Ali, Justine Penneroux, Reinaldo Dal Bello Jr, Aline Massé, Samuel Quentin et al.

Leukemia 2018 32 :1856 - 1860; February 26, 2018; 10.1038/s41375-018-0076-2

 

Abstract | Full Text

Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia

Elaine G. Garcia, Sowmya Iyer, Sara P. Garcia, Siebe Loontiens, Ruslan I. Sadreyev et al.

Leukemia 2018 32 :1860 - 1865; April 18, 2018; 10.1038/s41375-018-0130-0

 

Abstract | Full Text

Nucleolin promotes execution of the hematopoietic stem cell gene expression program

Csaba Mahotka, Sanil Bhatia, Jutta Kollet & Edgar Grinstein

Leukemia 2018 32 :1865 - 1868; March 08, 2018; 10.1038/s41375-018-0090-4

 

Abstract | Full Text

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

Massimo Gentile, Tait D. Shanafelt, Gianluigi Reda, Francesca Romana Mauro, Katja Zirlik et al.

Leukemia 2018 32 :1869 - 1873; March 20, 2018; 10.1038/s41375-018-0100-6

 

Abstract | Full Text

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS

Michael O. Alberti, Sridhar Nonavinkere Srivatsan, Jin Shao, Samantha N. McNulty, Gue Su Chang et al.

Leukemia 2018 32 :1874 - 1878; June 29, 2018; 10.1038/s41375-018-0193-y

 

Abstract | Full Text

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia

Jonathan Bond, Elise Labis, Alice Marceau-Renaut, Nicolas Duployez, Myriam Labopin et al.

Leukemia 2018 32 :1878 - 1882; June 27, 2018; 10.1038/s41375-018-0187-9

 

Abstract | Full Text

Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature